Investigators have developed a Uveal Melanoma Immunogenomic Score (UMIS) to predict which patients with metastatic uveal melanoma will respond to immunotherapy, according to findings published in Nature Communications.
Clinical Trials
Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma
This transcript has been edited for clarity.
Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.